Quick Answer
Can-Fite BioPharma Ltd. reported Cash and Equivalents of $5.53 million for fiscal year 2025.
Can-Fite BioPharma Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.53M | +14.6% |
| 2024 | $4.83M | +12.8% |
| 2023 | $4.28M | +43.7% |
| 2022 | $2.98M | -32.2% |
| 2021 | $4.39M | -46.9% |
| 2020 | $8.27M | +206.6% |
| 2019 | $2.70M | -25.4% |
| 2018 | $3.62M | +3.1% |
| 2017 | $3.50M | — |
- Can-Fite BioPharma Ltd. showed an increase of +14.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Can-Fite BioPharma Ltd.’s cash and equivalents has grown by 57.7% (from $3.50 million to $5.53 million).
- The most recent figure is from Can-Fite BioPharma Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: